Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

June 17, 2017

"We expect the expanded Sigma-Tau collaboration will help us realize the full potential of orBec? and oral BDP in the treatment of GI GVHD and other inflammatory GI diseases," stated Christopher J. Schaber, PhD, President and CEO of Soligenix. "We now have an experienced commercialization partner in the second major world market and we are pleased with the robust royalty rates that we have garnered through this strong business relationship.  There will also be significant economies of scale that we will realize through having one partner in both major territories.  This partnership will provide for the launch and commercialization of orBec? in North America and Europe, without any further related expense to Soligenix or its shareholders.  It also provides us with the potential for ongoing development funding across multiple indications for orBec? and oral BDP."  

SOURCE Soligenix, Inc.